Erschienen in:
01.06.2004 | Original
Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial
verfasst von:
Niall D. Ferguson, Robert M. Kacmarek, Jean-Daniel Chiche, Jeffrey M. Singh, David C. Hallett, Sangeeta Mehta, Thomas E. Stewart
Erschienen in:
Intensive Care Medicine
|
Ausgabe 6/2004
Einloggen, um Zugang zu erhalten
Abstract
Objectives
The American–European consensus conference (AECC) definition for acute respiratory distress syndrome (ARDS) requires a PaO2/FIO2≤200 mmHg, regardless of ventilator settings. We report the results of using standardized ventilator settings to screen and enroll ARDS patients in a clinical trial of high-frequency oscillatory ventilation (HFOV), including the impact on study enrollment, and potential effects on study outcome.
Design
Prospective cohort study.
Setting
Intensive care units in two teaching hospitals.
Participants
A consecutive sample of 41 patients with early ARDS by AECC criteria (baseline PaO2/FIO2≤200) who met all other inclusion/exclusion criteria for the HFOV trial.
Interventions
Patients were placed on standardized ventilator settings (tidal volume 7–8 ml/kg, PEEP 10 cmH2O, FIO2 1.0), and the PaO2/FIO2 was reassessed after 30 min.
Results
Seventeen patients (41.5%) had PaO2/FIO2 ratios that remained ≤200 mmHg [Persistent ARDS; PaO2/FIO2=94±36 (mean±SD)] and went on to inclusion in the HFOV study; however, in 24 patients (58.5%) the PaO2/FIO2 was >200 mmHg [Transient ARDS; PaO2/FIO2=310±74] and these patients were ineligible for the HFOV study. The ICU mortality was significantly greater (52.9 vs 12.5%; p=0.01) in the Persistent ARDS patients.
Conclusions
The use of these standardized ventilatory significantly impacted the PaO2/FIO2 ratio and therefore the ARDS prevalence and trial enrollment. These results have effects on the evaluation of the current ARDS literature and conduct of clinical trials in ARDS and hence consideration should be given to the use of standardized ventilatory settings in future ARDS trials.